Protocol Ledger

NCT05012254 · Phase II · ACTIVE NOT RECRUITING

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases

Interventional Phase II clinical trial protocol NCT05012254 sponsored by Fundación GECP in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-18 Enrollment: 71 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05012254
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)71 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05012254
Protocol FieldVerified Registry Value
NCT IdentifierNCT05012254
Consolidated Lead SponsorFundación GECP
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment71 participants (ACTUAL)
Registered Start Date2021-11-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05012254
Hospital Research SiteLocationSite Profile
Hospital Universitari Vall d'HebronBarcelona, SpainOpen Hospital Dossier ->
Hospital de La Santa Creu I Sant PauBarcelona, SpainOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI